North America Drugs Based on Gene Therapy Market by Deployment, by Applications, by Type, by End-User & by Technology 2032
North America Drugs Based on Gene Therapy Market was valued at USD 0.9 Billion in 2022 and is projected to reach USD 2.7 Billion by 2030, growing at a CAGR of 14.9% from 2024 to 2030.
North America has emerged as a pivotal hub for gene therapy advancements, with the market projected to reach USD 13,418.96 million by 2030, growing at a compound annual growth rate (CAGR) of 18.8% during the forecast period. This surge is driven by the escalating prevalence of genetic disorders and the escalating demand for innovative treatments. The market is segmented based on vector type, method, application, and end user, encompassing viral and non-viral vectors, ex-vivo and in-vivo methods, and applications ranging from oncological disorders to neurological diseases. The primary end users include cancer institutes, hospitals, and research institutes. The increasing research in gene therapy and its techniques and development is expected to boost market growth further. However, ethical and safety concerns while performing the method are expected to hamper the growth of the North America gene therapy market in the forecast period. The high cost of diagnostics and the lack of skilled and certified professionals are expected to challenge market growth. Despite these challenges, the market presents significant opportunities for growth, driven by the increasing demand for better quality healthcare for cancers and genetic disorders. The North America gene therapy market is expected to reach USD 13,418.96 million by 2030, at a CAGR of 18.8% during the forecast period. Product accounts for the most significant type segment in the market due to the growing use of exosome research products in diagnostics and therapeutics. The market's growth is further supported by the presence of key market players such as Biogen Inc., Alnylam Pharmaceuticals, Inc., and Sarepta Therapeutics, Inc., who are actively engaged in developing and commercializing gene therapy products. The increasing approval of gene therapies in North America, the availability of government funding for life science research, and growth in the pharmaceutical and biopharmaceutical industries have made North America the largest regional market for gene therapy. The market's expansion is also influenced by the rising focus on precision medicine and the development of advanced gene therapy techniques. The high cost of gene therapy products and complex regulatory frameworks and ethical concerns regarding genetic modifications may restrain market growth over the forecast period. However, the market's growth is mainly driven by factors such as growth in the number of regulatory approvals for gene therapy products, increasing investments in gene therapy research, among others. The increasing demand for better quality healthcare for cancers and genetic disorders is expected to boost the market’s growth. The North America gene therapy market is expected to reach USD 13,418.96 million by 2030, at a CAGR of 18.8% during the forecast period. Product accounts for the most significant type segment in the market due to the growing use of exosome research products in diagnostics and therapeutics. The market's growth is further supported by the presence of key market players such as Biogen Inc., Alnylam Pharmaceuticals, Inc., and Sarepta Therapeutics, Inc., who are actively engaged in developing and commercializing gene therapy products. The increasing approval of gene therapies in North America, the availability of government funding for life science research, and growth in the pharmaceutical and biopharmaceutical industries have made North America the largest regional market for gene therapy. The market's expansion is also influenced by the rising focus on precision medicine and the development of advanced gene therapy techniques. The high cost of gene therapy products and complex regulatory frameworks and ethical concerns regarding genetic modifications may restrain market growth over the forecast period. However, the market's growth is mainly driven by factors such as growth in the number of regulatory approvals for gene therapy products, increasing investments in gene therapy research, among others. The increasing demand for better quality healthcare for cancers and genetic disorders is expected to boost the market’s growth. The North America gene therapy market is expected to reach USD 13,418.96 million by 2030, at a CAGR of 18.8% during the forecast period. Product accounts for the most significant type segment in the market due to the growing use of exosome research products in diagnostics and therapeutics. The market's growth is further supported by the presence of key market players such as Biogen Inc., Alnylam Pharmaceuticals, Inc., and Sarepta Therapeutics, Inc., who are actively engaged in developing and commercializing gene therapy products. The increasing approval of gene therapies in North America, the availability of government funding for life science research, and growth in the pharmaceutical and biopharmaceutical industries have made North America the largest regional market for gene therapy. The market's expansion is also influenced by the rising focus on precision medicine and the development of advanced gene therapy techniques. The high cost of gene therapy products and complex regulatory frameworks and ethical concerns regarding genetic modifications may restrain market growth over the forecast period. However, the market's growth is mainly driven by factors such as growth in the number of regulatory approvals for gene therapy products, increasing investments in gene therapy research, among others. The increasing demand for better quality healthcare for cancers and genetic disorders is expected to boost the market’s growth. The North America gene therapy market is expected to reach USD 13,418.96 million by 2030, at a CAGR of 18.8% during the forecast period. Product accounts for the most significant type segment in the market due to the growing use of exosome research products in diagnostics and therapeutics. The market's growth is further supported by the presence of key market players such as Biogen Inc., Alnylam Pharmaceuticals, Inc., and Sarepta Therapeutics, Inc., who are actively engaged in developing and commercializing gene therapy products. The increasing approval of gene therapies in North America, the availability of government funding for life science research, and growth in the pharmaceutical and biopharmaceutical industries have made North America the largest regional market for gene therapy. The market's expansion is also influenced by the rising focus on precision medicine and the development of advanced gene therapy techniques. The high cost of gene therapy products and complex regulatory frameworks and ethical concerns regarding genetic modifications may restrain market growth over the forecast period. However, the market's growth is mainly driven by factors such as growth in the number of regulatory approvals for gene therapy products, increasing investments in gene therapy research, among others. The increasing demand for better quality healthcare for cancers and genetic disorders is expected to boost the market’s growth. The North America gene therapy market is expected to reach USD 13,418.96 million by 2030, at a CAGR of 18.8% during the forecast period. Product accounts for the most significant type segment in the market due to the growing use of exosome research products in diagnostics and therapeutics. The market's growth is further supported by the presence of key market players such as Biogen Inc., Alnylam Pharmaceuticals, Inc., and Sarepta Therapeutics, Inc., who are actively engaged in developing and commercializing gene therapy products. The increasing approval of gene therapies in North America, the availability of government funding for life science research, and growth in the pharmaceutical and biopharmaceutical industries have made North America the largest regional market for gene therapy. The market's expansion is also influenced by the rising focus on precision medicine and the development of advanced gene therapy techniques. The high cost of gene therapy products and complex regulatory frameworks and ethical concerns regarding genetic modifications may restrain market growth over the forecast period. However, the market's growth is mainly driven by factors such as growth in the number of regulatory approvals for gene therapy products, increasing investments in gene therapy research, among others. The increasing demand for better quality healthcare for cancers and genetic disorders is expected to boost the market’s growth. The North America gene therapy
Get an In-Depth Research Analysis of the Global Drugs Based on Gene Therapy Market Size And Forecast [2025-2032]
Who are the largest Global manufacturers in the Drugs Based on Gene Therapy industry?
- Biogen
- Novartis
- Gilead Sciences
- Sarepta Therapeutics
- Alnylam Pharmaceuticals
- Amgen
- Spark Therapeutics
- Akcea Therapeutics
- Bluebird bio
- Sunway Biotech
- SIBIONO
- AnGes
- Orchard Therapeutics
- Human Stem Cells Institute
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Drugs Based on Gene Therapy Market Size And Forecast [2025-2032]
What are the factors driving the growth of the Global Drugs Based on Gene Therapy Market?
Growing demand for below applications around the world has had a direct impact on the growth of the Global Drugs Based on Gene Therapy Market
- Neurological Diseases
- Cancer
- Other
What are the types of Drugs Based on Gene Therapy available in the Market?
Based on Types the Market is categorized into Below types that held the largest Drugs Based on Gene Therapy market share In 2023.
- Based on Viral
- Based on Non-viral
Which regions are leading the Global Drugs Based on Gene Therapy Market?
- Global (United States, Global and Mexico)
- Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
- Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
- South America (Brazil, Argentina, Columbia, etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Drugs Based on Gene Therapy Market Research Analysis
Detailed TOC of Global Drugs Based on Gene Therapy Market Research Report, 2024-2032
1. Introduction of the Global Drugs Based on Gene Therapy Market
- Overview of the Market
- Scope of Report
- Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
- Data Mining
- Validation
- Primary Interviews
- List of Data Sources
4. Global Drugs Based on Gene Therapy Market Outlook
- Overview
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Porters Five Force Model
- Value Chain Analysis
5. Global Drugs Based on Gene Therapy Market, By Type
6. Global Drugs Based on Gene Therapy Market, By Application
7. Global Drugs Based on Gene Therapy Market, By Geography
- Global
- Europe
- Asia Pacific
- Rest of the World
8. Global Drugs Based on Gene Therapy Market Competitive Landscape
- Overview
- Company Market Ranking
- Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768